Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic testing of breast and ovarian cancer patients: clinical characteristics and hormonal risk modifiers.

European journal of obstetrics, gynecology, and reproductive biology - 1 Jul 1999

Kaduri L, Gibs M, Hubert A, Sagi M, Heching N, Lerer I, Uziely B, Weinberg N, Abeliovich D, Peretz T

Abstract excerpt

OBJECTIVES: Carriers of the mutations 185delAG and 5382insC in the BRCA1 gene and 6174delT in the BRCA2 gene have a substantial life-time risk for breast and ovarian cancers (BC and OC). The aim of the study was to identify the clinical features and the hormonal risk modifiers in mutation carrier...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to BRCA2 Protein
Share to Genes, BRCA1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Carrier Screening

Share to Menarche

Share to Menopause

Share to Neoplasm Proteins

Share to Ovarian Neoplasms

Source

Identifiers

PMID: 10428326
DOI: 10.1016/s0301-2115(98)00286-3

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-10428326-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic testing of breast and ovarian cancer patients: clinical characteristics and hormonal risk modifiers.PMID 10428326Read ↗

BRCA1/2 carriers and endocrine risk modifiers.Semantic proximity Read ↗

Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer.Semantic proximity Read ↗

Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less.Semantic proximity Read ↗

[Clinical and molecular diagnosis of inherited breast-ovarian cancer].Semantic proximity Read ↗

Breast and ovarian cancer genetics and prevention.Semantic proximity Read ↗

Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.Semantic proximity Read ↗

Use of exogenous hormones in those at increased risk for breast cancer: contraceptive and menopausal hormones in gene carriers and other high-risk patients.Semantic proximity Read ↗

Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Breast cancer genetics in young women: What do we know?Semantic proximity Read ↗

Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.Semantic proximity Read ↗

Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.Semantic proximity Read ↗

[BRCA1- and BRCA2 mutations: Clinical management of patients with hereditary breast and ovarian cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.